Search

Your search keyword '"Adamo, Barbara"' showing total 314 results
Start Over Author "Adamo, Barbara"
314 results on '"Adamo, Barbara"'

1. Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer

Author

Lorman-Carbó, Natàlia, Martínez-Sáez, Olga, Fernandez-Martinez, Aranzazu, Galván, Patricia, Chic, Nuria, Garcia-Fructuoso, Isabel, Rodríguez, Adela, Gómez-Bravo, Raquel, Schettini, Francesco, Blasco, Paula, Castillo, Oleguer, González-Farré, Blanca, Adamo, Barbara, Vidal, Maria, Muñoz, Montserrat, Perou, Charles M., Malumbres, Marcos, Gavilá, Joaquín, Pascual, Tomás, Prat, Aleix, and Brasó-Maristany, Fara

Published
2024
Full Text
View/download PDF

2. Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)

Author

Turner, Nicholas, Saura, Cristina, Aftimos, Philippe, van den Tweel, Evelyn, Oesterholt, Mayke, Koper, Norbert, Colleoni, Marco, Kaczmarek, Emilie, Punie, Kevin, Song, Xinni, Armstrong, Anne, Bianchi, Giulia, Stradella, Agostina, Ladoire, Sylvain, Lim, Joline Si Jing, Quenel-Tueux, Nathalie, Tan, Tira J., Escrivá-de-Romaní, Santiago, OʼShaughnessy, Joyce, Kuip, Evelien, de Vries, Elisabeth G.E., Menke-van der Houven van Oordt, Willemien, Aftimos, Philippe, Papadimitriou, Konstantinos, Denys, Hannelore, Punie, Kevin, Jerusalem, Guy, Borms, Marleen, Duhoux, François, Turner, Nicholas, Macpherson, Iain, Armstrong, Anne, Levitt, Nicola, Palmieri, Carlo, Borley, Annabel, Crook, Timothy, Vega Alonso, Estela, Morales, Serafin, de Romani Muñoz, Santiago Escriva, Stradella, Agostina, Jerez Gilarranz, Yolanda, Anton, Antonio, Ponce, Jose Juan, Adamo, Barbara, Cortes Castan, Javier, Martinez, Maria, Petit, Thierry, Kaczmarek, Emilie, Ladoire, Sylvain, Quenel Tueux, Nathalie, Teixeira, Luis, Christophe Thery, Jean, Abadie-Lacourtoisie, Sophie, Lortholary, Alain, Luporsi, Elisabeth, Orfeuvre, Hubert, Bonnin, Nathalie, Bianchini, Giampaolo, Piacentini, Federico, Cognetti, Francesco, Marchetti, Paolo, Maiello, Evaristo, Cazzaniga, Marina, Guarneri, Valentina, Colleoni, Marco, Doni, Laura, Bordonaro, Roberto, Zamagni, Claudio, Bianchi, Giulia, Biganzoli, Laura, Thirlwell, Michael, Song, Xinni, Joy, Anil, Taylor, Sara, Helsten, Teresa, Chaudhry, Madhu, Ali, Haythem, Dakhil, Shaker, Mowat, Rex, Brufsky, Adam, Cobleigh, Melody, Modiano, Manuel, Cairo, Michelina, Meshad, Michael, Danso, Michael A., Andersen, Jay, Harroff, Allyson, Owera, Rami, Favret, Anne, OʼShaughnessy, Joyce, Pluard, Timothy, Rosenblatt, Paula, Jain, Sharad, Jensen, Jeanette Dupont, Jeppesen, Nina, Wedervang, Kim, Edlund, Per, Lindman, Henrik, Altena, Renske, Klint, Leif, Jing Ying, Tira Tan, and Si Jing, Joline Lim

Published
2024
Full Text
View/download PDF

4. A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies

Author

Conte, Benedetta, Brasó-Maristany, Fara, Hernández, Adela Rodríguez, Pascual, Tomás, Villacampa, Guillermo, Schettini, Francesco, Vidal Losada, Maria J., Seguí, Elia, Angelats, Laura, Garcia-Fructuoso, Isabel, Gómez-Bravo, Raquel, Lorman-Carbó, Natàlia, Paré, Laia, Marín-Aguilera, Mercedes, Martínez-Sáez, Olga, Adamo, Barbara, Sanfeliu, Esther, Fratini, Beatrice, Falato, Claudette, Chic, Núria, Vivancos, Ana, Villagrasa, Patricia, Staaf, Johan, Parker, Joel S., Perou, Charles M., and Prat, Aleix

Published
2024
Full Text
View/download PDF

5. Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study

Author

García-Corbacho, Javier, Indacochea, Alberto, González Navarro, Azucena E., Victoria, Iván, Moreno, Débora, Pesántez, David, Angelats, Laura, Modrego-Sanchez, Andrea, Sanfeliu, Esther, Castillo, Oleguer, Blasco, Paula, Mezquita, Laura, Viñolas, Nuria, Nogué, Miquel, Galván, Patricia, Adamo, Barbara, Basté, Neus, Sauri, Tamara, Juan, Manel, Prat, Aleix, and Schettini, Francesco

Published
2023
Full Text
View/download PDF

6. Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer

Author

Prat, Aleix, Brasó-Maristany, Fara, Martínez-Sáez, Olga, Sanfeliu, Esther, Xia, Youli, Bellet, Meritxell, Galván, Patricia, Martínez, Débora, Pascual, Tomás, Marín-Aguilera, Mercedes, Rodríguez, Anna, Chic, Nuria, Adamo, Barbara, Paré, Laia, Vidal, Maria, Margelí, Mireia, Ballana, Ester, Gómez-Rey, Marina, Oliveira, Mafalda, Felip, Eudald, Matito, Judit, Sánchez-Bayona, Rodrigo, Suñol, Anna, Saura, Cristina, Ciruelos, Eva, Tolosa, Pablo, Muñoz, Montserrat, González-Farré, Blanca, Villagrasa, Patricia, Parker, Joel S., Perou, Charles M., and Vivancos, Ana

Published
2023
Full Text
View/download PDF

7. Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

Author

Schettini, Francesco, Chic, Nuria, Brasó-Maristany, Fara, Paré, Laia, Pascual, Tomás, Conte, Benedetta, Martínez-Sáez, Olga, Adamo, Barbara, Vidal, Maria, Barnadas, Esther, Fernández-Martinez, Aranzazu, González-Farre, Blanca, Sanfeliu, Esther, Cejalvo, Juan Miguel, Perrone, Giuseppe, Sabarese, Giovanna, Zalfa, Francesca, Peg, Vicente, Fasani, Roberta, Villagrasa, Patricia, Gavilá, Joaquín, Barrios, Carlos H., Lluch, Ana, Martín, Miguel, Locci, Mariavittoria, De Placido, Sabino, and Prat, Aleix

Published
2023
Full Text
View/download PDF

8. Correction to: Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study

Author

García-Corbacho, Javier, Indacochea, Alberto, González Navarro, Azucena E., Victoria, Iván, Moreno, Débora, Pesántez, David, Angelats, Laura, Modrego-Sanchez, Andrea, Sanfeliu, Esther, Castillo, Oleguer, Blasco, Paula, Mezquita, Laura, Viñolas, Nuria, Nogué, Miquel, Galván, Patricia, Adamo, Barbara, Basté, Neus, Sauri, Tamara, Juan, Manel, Prat, Aleix, and Schettini, Francesco

Published
2023
Full Text
View/download PDF

9. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

Author

Prat, Aleix, Guarneri, Valentina, Paré, Laia, Griguolo, Gaia, Pascual, Tomás, Dieci, Maria V, Chic, Núria, González-Farré, Blanca, Frassoldati, Antonio, Sanfeliu, Esther, Cejalvo, Juan M, Muñoz, Montserrat, Bisagni, Giancarlo, Brasó-Maristany, Fara, Urso, Loredana, Vidal, Maria, Brandes, Alba A, Adamo, Barbara, Musolino, Antonino, Miglietta, Federica, Conte, Benedetta, Oliveira, Mafalda, Saura, Cristina, Pernas, Sònia, Alarcón, Jesús, Llombart-Cussac, Antonio, Cortés, Javier, Manso, Luis, López, Rafael, Ciruelos, Eva, Schettini, Francesco, Villagrasa, Patricia, Carey, Lisa A, Perou, Charles M, Piacentini, Federico, D'Amico, Roberto, Tagliafico, Enrico, Parker, Joel S, and Conte, Pierfranco

Published
2020
Full Text
View/download PDF

10. TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2– breast cancer

Author

Bardia, Aditya, primary, Jhaveri, Komal, additional, Kalinsky, Kevin, additional, Pernas, Sonia, additional, Tsurutani, Junji, additional, Xu, Binghe, additional, Hamilton, Erika, additional, Im, Seock-Ah, additional, Nowecki, Zbigniew, additional, Sohn, Joohyuk, additional, Laurentiis, Michelino De, additional, Jañez, Noelia Martínez, additional, Adamo, Barbara, additional, Lee, Keun Seok, additional, Jung, Kyung Hae, additional, Rubovszky, Gábor, additional, Tseng, Ling-Ming, additional, Lu, Yen-Shen, additional, Yuan, Yuan, additional, Maxwell, Micah J, additional, Haddad, Vincent, additional, Khan, Sabrina S, additional, Rugo, Hope S, additional, and Pistilli, Barbara, additional

Published
2024
Full Text
View/download PDF

11. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

Author

Schettini, Francesco, Chic, Nuria, Brasó-Maristany, Fara, Paré, Laia, Pascual, Tomás, Conte, Benedetta, Martínez-Sáez, Olga, Adamo, Barbara, Vidal, Maria, Barnadas, Esther, Fernández-Martinez, Aranzazu, González-Farre, Blanca, Sanfeliu, Esther, Cejalvo, Juan Miguel, Perrone, Giuseppe, Sabarese, Giovanna, Zalfa, Francesca, Peg, Vicente, Fasani, Roberta, Villagrasa, Patricia, Gavilá, Joaquín, Barrios, Carlos H., Lluch, Ana, Martín, Miguel, Locci, Mariavittoria, De Placido, Sabino, and Prat, Aleix

Published
2021
Full Text
View/download PDF

12. Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy

Author

Martínez-Sáez, Olga, Pascual, Tomás, Brasó-Maristany, Fara, Chic, Nuria, González-Farré, Blanca, Sanfeliu, Esther, Rodríguez, Adela, Martínez, Débora, Galván, Patricia, Rodríguez, Anna Belén, Schettini, Francesco, Conte, Benedetta, Vidal, Maria, Adamo, Barbara, Martínez, Antoni, Muñoz, Montserrat, Moreno, Reinaldo, Villagrasa, Patricia, Salvador, Fernando, Ciruelos, Eva M., Faull, Iris, Odegaard, Justin I., and Prat, Aleix

Published
2021
Full Text
View/download PDF

13. Frequency and spectrum of PIK3CA somatic mutations in breast cancer

Author

Martínez-Sáez, Olga, Chic, Nuria, Pascual, Tomás, Adamo, Barbara, Vidal, Maria, González-Farré, Blanca, Sanfeliu, Esther, Schettini, Francesco, Conte, Benedetta, Brasó-Maristany, Fara, Rodríguez, Adela, Martínez, Débora, Galván, Patricia, Rodríguez, Ana Belén, Martinez, Antonio, Muñoz, Montserrat, and Prat, Aleix

Published
2020
Full Text
View/download PDF

14. Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

Author

Brasó-Maristany, Fara, Griguolo, Gaia, Pascual, Tomás, Paré, Laia, Nuciforo, Paolo, Llombart-Cussac, Antonio, Bermejo, Begoña, Oliveira, Mafalda, Morales, Serafín, Martínez, Noelia, Vidal, Maria, Adamo, Barbara, Martínez, Olga, Pernas, Sonia, López, Rafael, Muñoz, Montserrat, Chic, Núria, Galván, Patricia, Garau, Isabel, Manso, Luis, Alarcón, Jesús, Martínez, Eduardo, Gregorio, Sara, Gomis, Roger R., Villagrasa, Patricia, Cortés, Javier, Ciruelos, Eva, and Prat, Aleix

Published
2020
Full Text
View/download PDF

15. Supplemental Methods from Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA–Wild-Type Triple-Negative Breast Cancer

Author

Karginova, Olga, primary, Siegel, Marni B., primary, Van Swearingen, Amanda E.D., primary, Deal, Allison M., primary, Adamo, Barbara, primary, Sambade, Maria J., primary, Bazyar, Soha, primary, Nikolaishvili-Feinberg, Nana, primary, Bash, Ryan, primary, O'Neal, Sara, primary, Sandison, Katie, primary, Parker, Joel S., primary, Santos, Charlene, primary, Darr, David, primary, Zamboni, William, primary, Lee, Yueh Z., primary, Miller, C. Ryan, primary, and Anders, Carey K., primary

Published
2023
Full Text
View/download PDF

16. Supplemental Table from Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA–Wild-Type Triple-Negative Breast Cancer

Author

Karginova, Olga, primary, Siegel, Marni B., primary, Van Swearingen, Amanda E.D., primary, Deal, Allison M., primary, Adamo, Barbara, primary, Sambade, Maria J., primary, Bazyar, Soha, primary, Nikolaishvili-Feinberg, Nana, primary, Bash, Ryan, primary, O'Neal, Sara, primary, Sandison, Katie, primary, Parker, Joel S., primary, Santos, Charlene, primary, Darr, David, primary, Zamboni, William, primary, Lee, Yueh Z., primary, Miller, C. Ryan, primary, and Anders, Carey K., primary

Published
2023
Full Text
View/download PDF

17. Supplemental Figure Legends from Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA–Wild-Type Triple-Negative Breast Cancer

Author

Karginova, Olga, primary, Siegel, Marni B., primary, Van Swearingen, Amanda E.D., primary, Deal, Allison M., primary, Adamo, Barbara, primary, Sambade, Maria J., primary, Bazyar, Soha, primary, Nikolaishvili-Feinberg, Nana, primary, Bash, Ryan, primary, O'Neal, Sara, primary, Sandison, Katie, primary, Parker, Joel S., primary, Santos, Charlene, primary, Darr, David, primary, Zamboni, William, primary, Lee, Yueh Z., primary, Miller, C. Ryan, primary, and Anders, Carey K., primary

Published
2023
Full Text
View/download PDF

18. Data from Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA–Wild-Type Triple-Negative Breast Cancer

Author

Karginova, Olga, primary, Siegel, Marni B., primary, Van Swearingen, Amanda E.D., primary, Deal, Allison M., primary, Adamo, Barbara, primary, Sambade, Maria J., primary, Bazyar, Soha, primary, Nikolaishvili-Feinberg, Nana, primary, Bash, Ryan, primary, O'Neal, Sara, primary, Sandison, Katie, primary, Parker, Joel S., primary, Santos, Charlene, primary, Darr, David, primary, Zamboni, William, primary, Lee, Yueh Z., primary, Miller, C. Ryan, primary, and Anders, Carey K., primary

Published
2023
Full Text
View/download PDF

19. Supplemental Figures S1-S9 from Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA–Wild-Type Triple-Negative Breast Cancer

Author

Karginova, Olga, primary, Siegel, Marni B., primary, Van Swearingen, Amanda E.D., primary, Deal, Allison M., primary, Adamo, Barbara, primary, Sambade, Maria J., primary, Bazyar, Soha, primary, Nikolaishvili-Feinberg, Nana, primary, Bash, Ryan, primary, O'Neal, Sara, primary, Sandison, Katie, primary, Parker, Joel S., primary, Santos, Charlene, primary, Darr, David, primary, Zamboni, William, primary, Lee, Yueh Z., primary, Miller, C. Ryan, primary, and Anders, Carey K., primary

Published
2023
Full Text
View/download PDF

20. Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial

Author

Adamo, Barbara, Bellet, Meritxell, Paré, Laia, Pascual, Tomás, Vidal, Maria, Pérez Fidalgo, José A., Blanch, Salvador, Martinez, Noelia, Murillo, Laura, Gómez-Pardo, Patricia, López-González, Ana, Amillano, Kepa, Canes, Jordi, Galván, Patricia, González-Farré, Blanca, González, Xavier, Villagrasa, Patricia, Ciruelos, Eva, and Prat, Aleix

Published
2019
Full Text
View/download PDF

21. Table S1 from Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer

Author

Cejalvo, Juan M., primary, Martínez de Dueñas, Eduardo, primary, Galván, Patricia, primary, García-Recio, Susana, primary, Burgués Gasión, Octavio, primary, Paré, Laia, primary, Antolín, Silvia, primary, Martinello, Rosella, primary, Blancas, Isabel, primary, Adamo, Barbara, primary, Guerrero-Zotano, Ángel, primary, Muñoz, Montserrat, primary, Nucíforo, Paolo, primary, Vidal, María, primary, Pérez, Ramón M., primary, Chacón López-Muniz, José I., primary, Caballero, Rosalía, primary, Peg, Vicente, primary, Carrasco, Eva, primary, Rojo, Federico, primary, Perou, Charles M., primary, Cortés, Javier, primary, Adamo, Vincenzo, primary, Albanell, Joan, primary, Gomis, Roger R., primary, Lluch, Ana, primary, and Prat, Aleix, primary

Published
2023
Full Text
View/download PDF

22. Figure S4 from Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer

Author

Cejalvo, Juan M., primary, Martínez de Dueñas, Eduardo, primary, Galván, Patricia, primary, García-Recio, Susana, primary, Burgués Gasión, Octavio, primary, Paré, Laia, primary, Antolín, Silvia, primary, Martinello, Rosella, primary, Blancas, Isabel, primary, Adamo, Barbara, primary, Guerrero-Zotano, Ángel, primary, Muñoz, Montserrat, primary, Nucíforo, Paolo, primary, Vidal, María, primary, Pérez, Ramón M., primary, Chacón López-Muniz, José I., primary, Caballero, Rosalía, primary, Peg, Vicente, primary, Carrasco, Eva, primary, Rojo, Federico, primary, Perou, Charles M., primary, Cortés, Javier, primary, Adamo, Vincenzo, primary, Albanell, Joan, primary, Gomis, Roger R., primary, Lluch, Ana, primary, and Prat, Aleix, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Figure Legends from A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor–positive HER2-negative Breast Cancer

Author

Prat, Aleix, primary, Tsai, Yi-Hsuan, primary, Pascual, Tomás, primary, Paré, Laia, primary, Adamo, Barbara, primary, Vidal, Maria, primary, Brasó-Maristany, Fara, primary, Galván, Patricia, primary, Brase, Jan Christoph, primary, Rodrik-Outmezguine, Vanessa, primary, Johnston, Stephen, primary, Ciruelos, Eva, primary, and Parker, Joel S., primary

Published
2023
Full Text
View/download PDF

24. Data from Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer

Author

Cejalvo, Juan M., primary, Martínez de Dueñas, Eduardo, primary, Galván, Patricia, primary, García-Recio, Susana, primary, Burgués Gasión, Octavio, primary, Paré, Laia, primary, Antolín, Silvia, primary, Martinello, Rosella, primary, Blancas, Isabel, primary, Adamo, Barbara, primary, Guerrero-Zotano, Ángel, primary, Muñoz, Montserrat, primary, Nucíforo, Paolo, primary, Vidal, María, primary, Pérez, Ramón M., primary, Chacón López-Muniz, José I., primary, Caballero, Rosalía, primary, Peg, Vicente, primary, Carrasco, Eva, primary, Rojo, Federico, primary, Perou, Charles M., primary, Cortés, Javier, primary, Adamo, Vincenzo, primary, Albanell, Joan, primary, Gomis, Roger R., primary, Lluch, Ana, primary, and Prat, Aleix, primary

Published
2023
Full Text
View/download PDF

25. Data from A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor–positive HER2-negative Breast Cancer

Author

Prat, Aleix, primary, Tsai, Yi-Hsuan, primary, Pascual, Tomás, primary, Paré, Laia, primary, Adamo, Barbara, primary, Vidal, Maria, primary, Brasó-Maristany, Fara, primary, Galván, Patricia, primary, Brase, Jan Christoph, primary, Rodrik-Outmezguine, Vanessa, primary, Johnston, Stephen, primary, Ciruelos, Eva, primary, and Parker, Joel S., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figures 1 - 5, Tables 1 - 4 from αB-Crystallin: A Novel Regulator of Breast Cancer Metastasis to the Brain

Author

Malin, Dmitry, primary, Strekalova, Elena, primary, Petrovic, Vladimir, primary, Deal, Allison M., primary, Al Ahmad, Abraham, primary, Adamo, Barbara, primary, Miller, C. Ryan, primary, Ugolkov, Andrey, primary, Livasy, Chad, primary, Fritchie, Karen, primary, Hamilton, Erika, primary, Blackwell, Kimberly, primary, Geradts, Joseph, primary, Ewend, Matt, primary, Carey, Lisa, primary, Shusta, Eric V., primary, Anders, Carey K., primary, and Cryns, Vincent L., primary

Published
2023
Full Text
View/download PDF

27. Supplemental Material from A PAM50-Based Chemoendocrine Score for Hormone Receptor–Positive Breast Cancer with an Intermediate Risk of Relapse

Author

Prat, Aleix, primary, Lluch, Ana, primary, Turnbull, Arran K., primary, Dunbier, Anita K., primary, Calvo, Lourdes, primary, Albanell, Joan, primary, de la Haba-Rodríguez, Juan, primary, Arcusa, Angels, primary, Chacón, José Ignacio, primary, Sánchez-Rovira, Pedro, primary, Plazaola, Arrate, primary, Muñoz, Montserrat, primary, Paré, Laia, primary, Parker, Joel S., primary, Ribelles, Nuria, primary, Jimenez, Begoña, primary, Bin Aiderus, Abdul Aziz, primary, Caballero, Rosalía, primary, Adamo, Barbara, primary, Dowsett, Mitch, primary, Carrasco, Eva, primary, Martín, Miguel, primary, Dixon, J. Michael, primary, Perou, Charles M., primary, and Alba, Emilio, primary

Published
2023
Full Text
View/download PDF

28. Figure S4 from A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor–positive HER2-negative Breast Cancer

Author

Prat, Aleix, primary, Tsai, Yi-Hsuan, primary, Pascual, Tomás, primary, Paré, Laia, primary, Adamo, Barbara, primary, Vidal, Maria, primary, Brasó-Maristany, Fara, primary, Galván, Patricia, primary, Brase, Jan Christoph, primary, Rodrik-Outmezguine, Vanessa, primary, Johnston, Stephen, primary, Ciruelos, Eva, primary, and Parker, Joel S., primary

Published
2023
Full Text
View/download PDF

29. Table S1 from A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor–positive HER2-negative Breast Cancer

Author

Prat, Aleix, primary, Tsai, Yi-Hsuan, primary, Pascual, Tomás, primary, Paré, Laia, primary, Adamo, Barbara, primary, Vidal, Maria, primary, Brasó-Maristany, Fara, primary, Galván, Patricia, primary, Brase, Jan Christoph, primary, Rodrik-Outmezguine, Vanessa, primary, Johnston, Stephen, primary, Ciruelos, Eva, primary, and Parker, Joel S., primary

Published
2023
Full Text
View/download PDF

30. Supplementary Data from Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor–Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti–HER2-Based Therapy

Author

Pascual, Tomás, primary, Fernandez-Martinez, Aranzazu, primary, Tanioka, Maki, primary, Dieci, M. Vittoria, primary, Pernas, Sonia, primary, Gavila, Joaquin, primary, Guarnieri, Valentina, primary, Cortes, Javier, primary, Villagrasa, Patricia, primary, Chic, Núria, primary, Vidal, Maria, primary, Adamo, Barbara, primary, Muñoz, Montserrat, primary, Griguolo, Gaia, primary, Llombart, Antonio, primary, Conte, Pierfranco, primary, Oliveira, Mafalda, primary, Conte, Benedetta, primary, Paré, Laia, primary, Galvan, Patricia, primary, Carey, Lisa A., primary, Perou, Charles M., primary, and Prat, Aleix, primary

Published
2023
Full Text
View/download PDF

31. Supplementary Data from Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial

Author

Ciruelos, Eva, primary, Villagrasa, Patricia, primary, Pascual, Tomás, primary, Oliveira, Mafalda, primary, Pernas, Sonia, primary, Paré, Laia, primary, Escrivá-de-Romaní, Santiago, primary, Manso, Luis, primary, Adamo, Barbara, primary, Martínez, Eduardo, primary, Cortés, Javier, primary, Vazquez, Silvia, primary, Perelló, Antonia, primary, Garau, Isabel, primary, Melé, Mireia, primary, Martínez, Noelia, primary, Montaño, Alvaro, primary, Bermejo, Begoña, primary, Morales, Serafin, primary, Echarri, María J., primary, Vega, Estela, primary, González-Farré, Blanca, primary, Martínez, Débora, primary, Galván, Patricia, primary, Canes, Jordi, primary, Nuciforo, Paolo, primary, Gonzalez, Xavier, primary, and Prat, Aleix, primary

Published
2023
Full Text
View/download PDF

32. Abstract P6-01-09: Efficacy of platinum-based chemotherapy and germline mutational status in early-stage triple-negative breast cancer: a unicenter retrospective analysis with long-term follow-up

Author

Hernández, Adela Rodríguez, primary, Conte, Benedetta, additional, Fernández, Laia, additional, Brasó-Maristany, Fara, additional, Pastor, Belén, additional, Potrony, Miriam, additional, Moreno, Lorena, additional, Grau, Elia, additional, Puig-Butillé, Joan Antón, additional, Sánchez, Aurora, additional, González-Farré, Blanca, additional, Sanfeliu, Esther, additional, Martínez-Sáez, Olga, additional, Falato, Claudette, additional, Vidal, Maria, additional, Chic, Nuria, additional, Pascual, Tomás, additional, Schettini, Francesco, additional, Muñoz, Montserrat, additional, Balaguer, Francesc, additional, Prat, Aleix, additional, and Adamo, Barbara, additional

Published
2023
Full Text
View/download PDF

33. Abstract P1-13-16: Dissecting the biological activity of different CDK4/6 inhibitors (CDK4/6i) in hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)

Author

Lorman-Carbó, Natàlia, primary, Martínez-Sáez, Olga, additional, Fernandez-Martinez, Aranzazu, additional, Galván, Patricia, additional, Chic, Nuria, additional, Adamo, Barbara, additional, Vidal, Maria, additional, Muñoz, Montserrat, additional, Perou, Charles M., additional, Gavilá, Joaquín, additional, Pascual, Tomás, additional, Prat, Aleix, additional, and Brasó-Maristany, Fara, additional

Published
2023
Full Text
View/download PDF

34. Abstract P2-23-16: Clinico-Pathological and Molecular Characterization of HER2-Enriched Breast Tumors Independently of HER2 Status

Author

Muñoz-Carrillo, Francisco Javier, primary, Paré, Laia, additional, Conte, Benedetta, additional, Rodríguez, Adela, additional, Galván, Patricia, additional, Sanfeliu, Esther, additional, González-Farré, Blanca, additional, Falato, Claudette, additional, Garcia-Fructuoso, Isabel, additional, Adamo, Barbara, additional, Chic, Nuria, additional, Martínez-Sáez, Olga, additional, Pascual, Tomás, additional, Moreno, Reinaldo, additional, Muñoz, Montserrat, additional, Brasó-Maristany, Fara, additional, Prat, Aleix, additional, Schettini, Francesco, additional, and Vidal, Maria, additional

Published
2023
Full Text
View/download PDF

35. Abstract OT3-11-02: SOLTI-1910: Predicting olaparib sensitivity in patients with unresectable locally advanced/metastatic HER2-negative breast cancer with BRCA1/2, PALB2, RAD51C/D mutations or HRD by the RAD51 test: RADIOLA TRIAL

Author

Balmaña, Judith, primary, Pascual, Tomás, additional, Llop-Guevara, Alba, additional, Tolosa, Pablo, additional, Blancas, Isabel, additional, Perez-Lopez, Maria-Eva, additional, Adamo, Barbara, additional, Teruel, Iris, additional, Ponce, Jose, additional, Gonzalez, Marta, additional, Viñas, Gemma, additional, Lema, Laura, additional, Salvador, Francisco Javier, additional, Martinez, Mª Teresa, additional, Espinosa, Alejandra, additional, Prat, Aleix, additional, and Serra, Violeta, additional

Published
2023
Full Text
View/download PDF

37. HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1

Author

Brasó-Maristany, Fara, primary, Griguolo, Gaia, additional, Chic, Nuria, additional, Pascual, Tomás, additional, Paré, Laia, additional, Maues, Julia, additional, Galván, Patricia, additional, Dieci, Maria Vittoria, additional, Miglietta, Federica, additional, Giarratano, Tommaso, additional, Martínez-Sáez, Olga, additional, Marín-Aguilera, Mercedes, additional, Schettini, Francesco, additional, Conte, Benedetta, additional, Angelats, Laura, additional, Vidal, Maria, additional, Adamo, Barbara, additional, Muñoz, Montserrat, additional, Sanfeliu, Esther, additional, González, Blanca, additional, Vivancos, Ana, additional, Villagrasa, Patricia, additional, Parker, Joel S, additional, Perou, Charles M, additional, Conte, PierFranco, additional, Prat, Aleix, additional, and Guarneri, Valentina, additional

Published
2022
Full Text
View/download PDF

38. PAM50 HER2-enriched subtype and pathological complete response in HER2-positive early breast cancer: a systematic review and meta-analysis

Author

Schettini, Francesco, Pascual, Tomas, Conte, Benedetta, Chic, Nuria, Brasò-Maristany, Fara, Galvàn, Patricia, Martìnez, Olga, Adamo, Barbara, Vidal, Maria, Muñoz, Montserrat, Fernandez-Martinez, Aranzazu, Rognoni, Carla, Griguolo, Gaia, Guarneri, Valentina, Conte, Pierfranco, Loccia, Mariavittoria, Brase, Jan, Gonzalez-Farre, Blanca, Villagrasa, Patricia, De Placido, Sabino, Schiff, Rachel, Rimawi, Mothaffar, Osborne, C, Pernas, Sonia, Perou, Charles, Carey, Lisa, and Prat, Aleix

Subjects
skin and connective tissue diseases, neoplasms
Abstract

HER2-positive (HER2+) breast cancer (BC) comprises all the PAM50 intrinsic molecular subtypes (Luminal A, Luminal B, HER2-E and Basal-like). Among them, the HER2-E is associated with higher pathological complete response (pCR) rates compared to non-HER2-E disease following anti-HER2-based regimens, with or without chemotherapy (CT). Here, we present a trial-level metanalysis to validate the association of the HER2-E subtype with pCR.

Published
2022
Full Text
View/download PDF

39. Abstract P4-07-08: Prognostic value of intrinsic subtypes (IS) in hormone receptor-positive (HoR+) metastatic breast cancer (MBC): A systematic review and meta-analysis of prospective trials

Author

Schettini, Francesco, primary, Martínez-Sáez, Olga, additional, Chic, Nuria, additional, Brasó-Maristany, Fara, additional, Galván, Patricia, additional, Martínez, Debora, additional, Paré, Laia, additional, Vidal, Maria, additional, Adamo, Barbara, additional, Muñoz, Montserrat, additional, Pascual, Tomás, additional, Ciruelos, Eva, additional, Perou, Charles M, additional, Carey, Lisa A, additional, and Prat, Aleix, additional

Published
2022
Full Text
View/download PDF

40. Abstract P4-11-28: Collecting quality of life information in a cohort of breast cancer survivors- Integrating electronic data collection into clinical practice

Author

Amat, Clara, primary, Fuentes, Ángeles, additional, Grau, Imma, additional, Lozano-Rubí, Raimundo, additional, Martinez-Sáez, Olga, additional, Chic, Nuria, additional, Adamo, Barbara, additional, Vidal, Maria, additional, Fernandez, Irene, additional, Valachis, Antonis, additional, Kosmidis, Thanos, additional, Kokkonidis, Miltiadis, additional, and Muñoz, Montserrat, additional

Published
2022
Full Text
View/download PDF

41. Abstract PD8-03: Palbociclib and trastuzumab for HER2-positive metastatic breast cancer (SOLTI-1303 PATRICIA): Final results from cohort A and B, prospective, open-label, multicenter phase II study

Author

Ciruelos, Eva, primary, Pascual, Tomás, additional, Oliveira, Mafalda, additional, Escrivá-de-Romaní, Santiago, additional, Pernas, Sonia, additional, Paré, Laia, additional, Adamo, Barbara, additional, Martínez, Eduardo, additional, Cortés, Javier, additional, Perelló, Antonia, additional, Galan, Maria, additional, Melé, Mireia, additional, Tolosa, Pablo, additional, González-Farré, Blanca, additional, Galván, Patricia, additional, Canes, Jordi, additional, Nuciforo, Paolo, additional, Gonzalez, Xavier, additional, Villagrasa, Patricia, additional, and Prat, Aleix, additional

Published
2022
Full Text
View/download PDF

42. HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1.

Author

Brasó-Maristany, Fara, Griguolo, Gaia, Chic, Nuria, Pascual, Tomás, Paré, Laia, Maues, Julia, Galván, Patricia, Dieci, Maria Vittoria, Miglietta, Federica, Giarratano, Tommaso, Martínez-Sáez, Olga, Marín-Aguilera, Mercedes, Schettini, Francesco, Conte, Benedetta, Angelats, Laura, Vidal, Maria, Adamo, Barbara, Muñoz, Montserrat, Sanfeliu, Esther, and González, Blanca

Subjects
HER2 positive breast cancer, GENE expression, DISEASE risk factors, ANTIBODY-drug conjugates, HORMONE receptors
Abstract

In advanced HER2-positive (HER2+) breast cancer, the new antibody-drug conjugate trastuzumab deruxtecan is more effective compared with trastuzumab emtansine (T-DM1). However, trastuzumab deruxtecan can have considerable toxicities, and the right treatment sequence is unknown. Biomarkers to guide the use of anti-HER2 therapies beyond HER2 status are needed. Here, we evaluated if preestablished levels of ERBB2 mRNA expression according to the HER2DX standardized assay are associated with response and survival following T-DM1. In ERBB2 low, medium, and high groups, the overall response rate was 0%, 29%, and 56%, respectively (P  <  .001). ERBB2 mRNA was statistically significantly associated with better progression-free survival (P  = .002) and overall survival (OS; P  =  .02). These findings were independent of HER2 immunohistochemistry (IHC) levels, hormone receptor, age, brain metastasis, and line of therapy. The HER2DX risk score (P  = .04) and immunoglobulin signature (P  = .04) were statistically significantly associated with overall survival since diagnosis. HER2DX provides prognostic and predictive information following T-DM1 in advanced HER2+ breast cancer. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

45. Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy

Author

Chic, Nuria, primary, Schettini, Francesco, additional, Brasó-Maristany, Fara, additional, Sanfeliu, Esther, additional, Adamo, Barbara, additional, Vidal, Maria, additional, Martínez, Débora, additional, Galván, Patricia, additional, González-Farré, Blanca, additional, Cortés, Javier, additional, Gavilá, Joaquín, additional, Saura, Cristina, additional, Oliveira, Mafalda, additional, Pernas, Sònia, additional, Martínez-Sáez, Olga, additional, Soberino, Jesús, additional, Ciruelos, Eva, additional, Carey, Lisa A., additional, Muñoz, Montserrat, additional, Perou, Charles M., additional, Pascual, Tomás, additional, Bellet, Meritxell, additional, and Prat, Aleix, additional

Published
2021
Full Text
View/download PDF

46. Independent validation of the PAM50-based Chemo-Endocrine Score in hormonal receptor positive HER2-positive breast cancer treated with neoadjuvant therapy

Author

Pascual, Tomás, Fernandez-Martinez, Aranzazu, Tanioka, Maki, Dieci, Maria Vittoria, Pernas, Sonia, Gavilá, Joaquín, Guarneri, Valentina, Cortés, Javier, Villagrasa, Patricia, Chic, Nuria, Vidal, María, Adamo, Barbara, Muñoz, Montserrat, Griguolo, Gaia, Llombart-Cussac, Antonio, Conte, Pierfranco, Oliveira, Mafalda, Conte, Benedetta, Paré, Laia, Galván, Patricia, Carey, Lisa A, Perou, Charles M, and Prat, Aleix

Published
2021

47. Gene expression profiles of breast cancer metastasis according to organ site

Author

Brasó‐Maristany, Fara, primary, Paré, Laia, additional, Chic, Nuria, additional, Martínez‐Sáez, Olga, additional, Pascual, Tomás, additional, Mallafré‐Larrosa, Meritxell, additional, Schettini, Francesco, additional, González‐Farré, Blanca, additional, Sanfeliu, Esther, additional, Martínez, Débora, additional, Galván, Patricia, additional, Barnadas, Esther, additional, Salinas, Belinda, additional, Tolosa, Pablo, additional, Ciruelos, Eva, additional, Carcelero, Esther, additional, Guillén, Cecilia, additional, Adamo, Barbara, additional, Moreno, Reinaldo, additional, Vidal, Maria, additional, Muñoz, Montserrat, additional, and Prat, Aleix, additional

Published
2021
Full Text
View/download PDF

48. ERBB2mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer

Author

Griguolo, Gaia, Braso-Maristany, Fara, Gonzalez-Farre, Blanca, Pascual, Tomas, Chic, Nuria, Sauri, Tamara, Kates, Ronald, Gluz, Oleg, Martinez, Debora, Pare, Laia, Tsvetkova, Vassilena, Pesantez, David, Vidal, Maria, Adamo, Barbara, Munoz, Montserrat, Galvan, Patricia, Barbera, Laura, Cuatrecasas, Miriam, Christgen, Mathias, Kreipe, Hans, Monge-Escartin, Ines, Villagrasa, Patricia, Soy, Dolors, Giarratano, Tommaso, Dieci, Maria Vittoria, Conte, Pierfranco, Harbeck, Nadia, Guarneri, Valentina, Prat, Aleix, Griguolo, Gaia, Braso-Maristany, Fara, Gonzalez-Farre, Blanca, Pascual, Tomas, Chic, Nuria, Sauri, Tamara, Kates, Ronald, Gluz, Oleg, Martinez, Debora, Pare, Laia, Tsvetkova, Vassilena, Pesantez, David, Vidal, Maria, Adamo, Barbara, Munoz, Montserrat, Galvan, Patricia, Barbera, Laura, Cuatrecasas, Miriam, Christgen, Mathias, Kreipe, Hans, Monge-Escartin, Ines, Villagrasa, Patricia, Soy, Dolors, Giarratano, Tommaso, Dieci, Maria Vittoria, Conte, Pierfranco, Harbeck, Nadia, Guarneri, Valentina, and Prat, Aleix

Abstract

Trastuzumab emtansine (T-DM1) is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive (HER2+) metastatic breast cancer (BC) and for residual disease after neoadjuvant therapy; however, not all patients benefit. Here, we hypothesized that the heterogeneity in the response seen in patients is partly explained by the levels of human epidermal growth factor receptor 2 gene(ERBB2)mRNA. We analyzedERBB2expression using a clinically applicable assay in formalin-fixed paraffin-embedded (FFPE) tumors (primary or metastatic) from a retrospective series of 77 patients with advanced HER2+ BC treated with T-DM1. The association ofERBB2levels and response was further validated in 161 baseline tumors from the West German Study (WGS) Group ADAPT phase II trial exploring neoadjuvant T-DM1 and 9 in vitro BC cell lines. Finally,ERBB2expression was explored in 392 BCs from an in-house dataset, 368 primary BCs from The Cancer Genome Atlas (TCGA) dataset and 10,071 tumors representing 33 cancer types from the PanCancer TCGA dataset. HighERBB2mRNA was found associated with better response and progression-free survival in the metastatic setting and higher rates of pathological complete response in the neoadjuvant setting.ERBB2expression also correlated with in vitro response to T-DM1. Finally, our assay identified 0.20-8.41% of tumors across 15 cancer types asERBB2-high, including gastric and esophagus adenocarcinomas, urothelial carcinoma, cervical squamous carcinoma and pancreatic cancer. In particular, we identified highERBB2mRNA in a patient with HER2+ advanced gastric cancer who achieved a long-lasting partial response to T-DM1. Our study demonstrates that the heterogeneity in response to T-DM1 is partly explained byERBB2levels and provides a clinically applicable assay to be tested in future clinical trials of breast cancer and other cancer types.

Published
2020

49. Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor–Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti–HER2-Based Therapy

Author

Pascual, Tomás, primary, Fernandez-Martinez, Aranzazu, additional, Tanioka, Maki, additional, Dieci, M. Vittoria, additional, Pernas, Sonia, additional, Gavila, Joaquin, additional, Guarnieri, Valentina, additional, Cortes, Javier, additional, Villagrasa, Patricia, additional, Chic, Núria, additional, Vidal, Maria, additional, Adamo, Barbara, additional, Muñoz, Montserrat, additional, Griguolo, Gaia, additional, Llombart, Antonio, additional, Conte, Pierfranco, additional, Oliveira, Mafalda, additional, Conte, Benedetta, additional, Paré, Laia, additional, Galvan, Patricia, additional, Carey, Lisa A., additional, Perou, Charles M., additional, and Prat, Aleix, additional

Published
2021
Full Text
View/download PDF

50. Abstract PS18-11: Molecular characterization of advanced breast cancer according to site of metastasis

Author

Brasó-Maristany, Fara, primary, Paré, Laia, additional, Chic, Núria, additional, Martínez-Sáez, Olga, additional, Pascual, Tomás, additional, Mallafré, Meritxell, additional, González-Farré, Blanca, additional, Sanfeliu, Esther, additional, Martínez, Débora, additional, Galván, Patricia, additional, Salinas, Belinda, additional, Adamo, Barbara, additional, Moreno, Reinaldo, additional, Vidal, Maria, additional, Muñoz, Montserrat, additional, and Prat, Aleix, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results